Optimer Pharmaceuticals Inc (OPTR.OQ)

OPTR.OQ on NASDAQ Stock Exchange Global Select Market

12.61USD
1 Aug 2013
Price Change (% chg)

$0.10 (+0.80%)
Prev Close
$12.51
Open
$12.64
Day's High
$12.65
Day's Low
$12.60
Volume
25,292
Avg. Vol
324,197
52-wk High
$16.77
52-wk Low
$8.66

OPTR.OQ

Chart for OPTR.OQ

About

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company’s development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development... (more)

Overall

Beta: 0.45
Market Cap (Mil.): $609.50
Shares Outstanding (Mil.): 48.72
Dividend: --
Yield (%): --

Financials

  OPTR.OQ Industry Sector
P/E (TTM): -- 37.93 37.76
EPS (TTM): -1.20 -- --
ROI: -46.93 19.48 18.76
ROE: -47.34 20.17 19.59
Search Stocks

Cubist to pay up to $1.6 billion for two antibiotics makers

- Cubist Pharmaceuticals Inc has agreed to pay up to $1.6 billion for Trius Therapeutics Inc and Optimer Pharmaceuticals Inc, expanding its heft in antibiotics at a time when the number of drug-resistant viruses are on the rise.

30 Jul 2013

UPDATE 2-Cubist to pay up to $1.6 bln for two antibiotics makers

* Cubist sees the sum of both deals to be accretive in 2015

30 Jul 2013

Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 billion

- Cubist Pharmaceuticals Inc said it would buy Trius Therapeutics Inc and Optimer Pharmaceuticals Inc for up to $1.62 billion to boost its antibiotics portfolio.

30 Jul 2013

CORRECTED-Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 bln

(Corrects paragraphs 2 and 3 to say the per-share offers include contingency payments)

30 Jul 2013

Cubist bid for Optimer before sale process began: sources

NEW YORK - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.

15 May 2013

Cubist bid almost $1 bln for Optimer before sale process-sources

NEW YORK, May 15 - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.

15 May 2013

Optimer shares rise after report names Glaxo, Cubist as potential buyers

- Shares of Optimer Pharmaceuticals Inc rose as much as 24 percent after a Bloomberg report said GlaxoSmithKline Plc and Cubist Pharmaceuticals Inc were among those interested in buying the antibiotic maker.

02 Apr 2013

UPDATE 1-Optimer shares rise after report names Glaxo, Cubist as potential buyers

* Shares up 18 pct (Adds comments from an analyst, details)

02 Apr 2013

Optimer Pharma exploring sale, shares jump

- Drugmaker Optimer Pharmaceuticals Inc said it was exploring a sale and replaced its chief executive as part of a review of compliance issues, sending its shares up 19 percent.

27 Feb 2013

Optimer Pharma exploring sale, shares jump

- Optimer Pharmaceuticals Inc said it was exploring a possible sale of the company among a full range of alternatives and that Chairman Henry McKinnell would act as chief executive for the duration of the review process.

27 Feb 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Quantitative Report
$69.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks